PACS software drives ISG's growth

Article

ISG Technologies continues to move forward from its proxy fight of a year ago. The Mississauga, Ontario-based medical imaging software developer reported an 8% increase in revenue for its 1998 fiscal first quarter, bringing sales to a company record for

ISG Technologies continues to move forward from its proxy fight of a year ago. The Mississauga, Ontario-based medical imaging software developer reported an 8% increase in revenue for its 1998 fiscal first quarter, bringing sales to a company record for the period.

ISG reported revenues of $5.8 million (U.S.) for the period (end-September), compared with $5.4 million in the first quarter of 1997. Net income was $6400, compared with a net loss of $780,000 in the same period last year. No extraordinary charges were reported during the quarter. The company increased its backlog during the period by more than $6.3 million, representing multiyear agreements for licensed software and contract engineering work, according to the firm.

While revenues from the company's image-guided surgery line were down significantly, substantial gains in sales of ISG's Viewing and Reading Station (VRS) PACS software offset the loss, resulting in overall flat revenues of $2.8 million for the company's licensed software efforts. Contract R&D revenues rose 48% to $2.8 million.

The company also reported favorable developments in its IAP medical imaging console software business. In other quarterly developments, ISG released a Windows NT version of its VRS product line. Previously, VRS was based exclusively on the Unix operating system.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Diagnostic Imaging’s Top Five Breast Imaging Content: Summer 2025
Reducing Mammography Workload by Nearly 40 Percent? What a New Hybrid AI Study Reveals
 What New Research Reveals About Portable Low-Field MRI and Patients with Suspected Alzheimer’s Disease
© 2025 MJH Life Sciences

All rights reserved.